Harness Therapeutics
Generated by Meeveem AI
"Unlocking new targets to transform the treatment of neurodegenerative diseases"
Cambridge
•11 - 50 Employees
•Biotechnology
About Harness Therapeutics
Harness Therapeutics develops precision medicines for neurodegenerative diseases including Huntington's disease, Parkinson's disease, Alzheimer's disease and ALS. Using its MISBA platform, the company targets genetically validated disease-modifying pathways that traditional therapies cannot reach. The platform enables controlled protein upregulation for safe intervention in complex biological systems. The lead programme targets FAN1, a DNA repair nuclease linked to delayed Huntington's disease onset. Harness is the first to drug this critical target, potentially enabling disease-modifying treatment before symptoms appear. The Cambridge-based company is supported by expert advisors in RNA biology and neurodegeneration.
23
Team Members
2020
Founded
Biotechnology
Sector
On-Site
Work Environment
Our Vision
A future where neurodegenerative diseases are detected early and treated early with precision medicines to alter the course of disease, unlocking longer, healthier lives for millions worldwide.
Our Mission
At Harness Therapeutics, our mission is to develop disease-modifying therapies for neurodegenerative diseases that deliver meaningful, lasting impact for patients.